Inventiva S.A. Business Summary

Inventiva S.A. is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, R&D milestones, and royalty-bearing partnerships, most notably its collaboration with CTTQ (Sino Biopharm) for the Greater China market. The company’s business model focuses on the development of oral small-molecule therapies, with its primary segment dedicated to metabolic dysfunction-associated steatohepatitis (MASH) and a secondary focus on rare diseases such as mucopolysaccharidosis. Its lead product candidate, lanifibranor, is a pan-PPAR agonist currently in Phase 3 clinical trials. In the competitive landscape, Inventiva contends with Madrigal Pharmaceuticals, Akero Therapeutics, and 89bio. While Madrigal holds the first-mover advantage with the first FDA-approved MASH treatment, Inventiva differentiates itself as the only player utilizing a pan-PPAR mechanism designed to address the full spectrum of MASH pathology, including fibrosis, inflammation, and insulin sensitivity. The company was co-founded in 2012 by Frédéric Cren (Chairman and CEO) and Pierre Broqua (Chief Scientific Officer), both of whom previously held senior leadership positions at Fournier Laboratories and Abbott. Cren brings a background in strategic management from his tenure at Boston Consulting Group and Abbott’s healthcare division, while Broqua is a renowned pharmacologist credited with the discovery of several successful compounds in the metabolic space. The executive team is further supported by CFO Benoît Gueugnon, who oversees the firm’s dual-listing on Euronext Paris and Nasdaq. Inventiva is backed by a high-profile syndicate of institutional investors, including New Enterprise Associates (NEA), BVF Partners, Novo Holdings, and Sofinnova Partners, following a transformative €348 million financing round in late 2024 that secured the company's path through its pivotal Phase 3 NATiV3 trial results.